ERGO.L Share News (ERGO)

Ergomed Sinks To Interim Loss As Costs Rise In Spite Of Revenue Growth

LONDON (Alliance News) - Pharmaceutical services company Ergomed PLC said on Wednesday it swung to a loss for the first half of 2018 due to higher expenses and in spite of revenue the six months a

Ergomed Appoints Stuart Jackson As Chief Financial Officer

LONDON (Alliance News) - Pharmaceutical services provider Ergomed PLC said on Monday it has appointed Stuart Jackson as chief financial officer with immediate effect.Previously, Jackson was

Strategic Equity Takes Holding In Ergomed Across Notifiable Threshold

LONDON (Alliance News) - Ergomed PLC said Tuesday that Strategic Equity Capital PLC took its stake in the company to 5.3%.Prior to Monday's transaction it was not disclosed what holding

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 5 April ElectrocomponentsTrading statementHSS Hire GroupFull Year Year Airlines

Ergomed reports positive results from insomnia drug trial

(ShareCast News) - AIM-listed pharma company Ergomed on Monday reported positive top-line results from a Phase II clinical trial of Lorediplon in patients with insomnia with its co-development partner Ferrer. The company said both 5 and 10mg Lorediplon met the primary endpoint with "high statistical

Ergomed buys drug safety and regulatory consultancy for £4m

(ShareCast News) - AIM-listed pharmaceutical Ergomed has bought Prague-based European PharmInvent Services for €4.8m (£4.1m), in order to grow its services business. The acquisition of PharmInvent, a drug safety and regulatory consultancy, will expand the company's pharmacovigilance division, PrimeV

Ergomed Boosts PrimeVigilance Division By Purchasing PharmInvent (ALLISS)

Ergomed Co-Development Partner Plans Name Change And Listing

Ergomed to benefit from Zoptrex Australasia deal

(ShareCast News) - Specialised pharmaceutical services company Ergomed announced on Friday that its co-development partner, Aeterna Zentaris, has signed an additional licensing agreement for Zoptrex. The AIM-traded firm said Aeterna Zentaris signed an exclusive license agreement on Wednesday with Sp

UK Earnings, Trading Statements Calendar - Next 7 Days

Ergomed wins two licenses for cancer drug Zoptrex

(ShareCast News) - Pharmaceutical service provider Ergomed's development partner Aeterna Zentaris, won two licensing deals for its cancer drug Zoptrex gaining new territory in Southeast Asia and the Middle East. In July 2016 Aeterna Zentaris signed a license agreement with affiliates of Orient EuroP

UK Shareholder Meetings Calendar - Next 7 Days

Ergomed Opens New US Office For PrimeVigilance Business Outside Boston

Ergomed buys two German service companies

(ShareCast News) - Ergomed, a British pharmaceutical development services company, said on Monday, it had bought two German service providers to complement and enhance its existing capabilities, and increase its presence in Germany. The company acquired Dr. Oestreich + Partner GmbH (O+P), a full ser

Ergomed Buys Two German Service Providers To Enhance Capabilities (ALLISS)